Standout Papers

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implicatio... 2008 2026 2014 2020 810
  1. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease (2009)
    Clifford R. Jack, Val J. Lowe et al. Brain
  2. Recommendations on the Use of 18F-FDG PET in Oncology (2008)
    James Fletcher, Benjamin Djulbegović et al. Journal of Nuclear Medicine
  3. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment (2008)
    Clifford R. Jack, Val J. Lowe et al. Brain
  4. Defining imaging biomarker cut points for brain aging and Alzheimer's disease (2016)
    Clifford R. Jack, Heather J. Wiste et al. Alzheimer s & Dementia
  5. Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography (2018)
    Michelle M. Mielke, Clinton E. Hagen et al. Alzheimer s & Dementia
  6. An autoradiographic evaluation of AV-1451 Tau PET in dementia (2016)
    Val J. Lowe, Geoffry L. Curran et al. Acta Neuropathologica Communications
  7. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0 (2018)
    Ian Law, Nathalie L. Albert et al. European Journal of Nuclear Medicine and Molecular Imaging
  8. Longitudinal tau PET in ageing and Alzheimer’s disease (2018)
    Clifford R. Jack, Heather J. Wiste et al. Brain
  9. Performance of plasma phosphorylated tau 181 and 217 in the community (2022)
    Michelle M. Mielke, Jeffrey L. Dage et al. Nature Medicine
  10. Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research (2021)
    Christina M. Moloney, Val J. Lowe et al. Alzheimer s & Dementia
  11. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes (2021)
    Michelle M. Mielke, Ryan D. Frank et al. JAMA Neurology
  12. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging (2023)
    Jeremiah A. Aakre, Vijay K. Ramanan et al. Neurology

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 210 standout
Sub-graph 1 of 15

Citing Papers

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
2025 Standout
Mechanisms of sex differences in Alzheimer’s disease
2024 Standout
163 intermediate papers

Works of Val J. Lowe being referenced

Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration
2018
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly
2012
and 74 more

Author Peers

Author Last Decade Papers Cites
Val J. Lowe 9766 10442 7031 567 25.2k
Andrew J. Saykin 12161 7067 3984 733 33.4k
Lars‐Olof Wahlund 9208 8094 3812 437 23.9k
Wiesje M. van der Flier 16264 14298 4707 777 33.3k
Stephen D. Weigand 11827 12083 4630 217 24.0k
Satoshi Minoshima 6260 8622 5062 425 34.8k
Joel H. Kramer 11253 7617 3626 464 27.2k
Karl Herholz 4482 3823 6002 269 17.3k
Leslie M. Shaw 15815 16704 3750 359 32.9k
Alexander Drzezga 4909 4787 5485 370 15.3k
Christopher C. Rowe 9706 11402 3648 404 20.6k

All Works

Loading papers...

Rankless by CCL
2026